Trademarkia Logo

Canada

C$
Trademark Search in Canada
POSIFLO

View On IC.GC.CA

POSIFLO
REGISTERED

on 10 Sept 2019

Last Applicant/ Owned by

GLAXO GROUP LIMITED

GSK Medicines Research CentreGunnels Wood RoadStevenage, SG1 2NY

GB

Serial Number

1751423 filed on 21st Oct 2015

Registration Number

TMA1053443 registered on 10th Sept 2019

Registration expiry Date

10th Sept 2029

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

POSIFLO

Trademark usage description

pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficien Read More

Classification Information

Class [005]
Pharmaceutical preparations for use as anti-infectives; Pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus (HPV), respiratory syncytial virus (RSV), hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; Pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants; Pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; Pharmaceutical preparations for the treatment of atherosclerosis; Pharmaceutical preparations for the treatment of viral conditions namely human immunodeficiency virus (HIV), HPV, RSV, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; Pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; Pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; Pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; Pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; Pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; Pharmaceutical preparations for use in ophthalmology; Pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; Pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone/androgen disorders and estrogen disorders; Pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; Pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder; Pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; Pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility; Pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; Pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, Leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; Pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; Pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome; Pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; Pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); Pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; Pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; Pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; Pharmaceutical preparations for the treatment of malaria; Pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines namely prophylactic and therapeutic vaccines for humans; Pharmaceutical preparations for the treatment of neurological diseases and disorders namely Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, insomnia; Pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses; Pharmaceutical preparations for the treatment of muscular dystrophy

Classification kind code

10

Class [044]
Cell and gene therapy services

Classification kind code

10

Mark Details

Serial Number

1751423

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 50
on 10th Jun 2016		Allowed
Submitted for opposition 68
on 25th Feb 2016		Rep for Service Name Changed
Submitted for opposition 67
on 25th Feb 2016		Agent Name Changed
Submitted for opposition 42
on 24th Feb 2016		Advertised
Submitted for opposition 26
on 28th Jan 2016		Approved
Submitted for opposition 22
on 11th Dec 2015		Search Recorded
Submitted for opposition 27
on 11th Dec 2015		Approval Notice Sent
Submitted for opposition 31
on 27th Oct 2015		Formalized
Submitted for opposition 1
on 22nd Oct 2015		Created
Submitted for opposition 30
on 21st Oct 2015		Filed